Abstract
Objective
To evaluate the evolution of disease-related symptoms and its relationship with the control of the disease in first-line treatment in patients with metastatic non-small cell lung cancer (NSCLC).
Methods
This was an observational, prospective, national and multicentre study with two visits in which the following were collected: (1) baseline visit: sociodemographic and clinical variables (2) visit after completing the 4–6 chemotherapy cycles: criteria for ending treatment, control of the disease and clinical variables. Ad hoc questionnaires were collected to assess the frequency of symptoms (evaluated by the patient), and quality-of-life questionnaires to assess the intensity of symptoms (using the Lung Cancer Symptom Scale, LCSS), and interference in the patient’s daily life, assessed by the patient and by the investigator.
Results
A total of 155 patients were included. Patients predominantly described tiredness (24.1%) and pain (23.9%) as the symptoms that appeared “frequently or continuously”. A statistically significant decrease in scores for symptoms of cough (15.4 points), dyspnoea (8.5 points), pain (9.5 points) and discomfort related to their illness (9 points) was observed between visits. Patients who achieved a complete or partial response showed a statistically significant reduction in the cough, dyspnoea, pain and disconfort frequency. Regarding the intensity, cough was the only symptom that showed a statistically significant decrease for both the patient and the investigator. Tiredness/asthenia and pain were the symptoms with the greatest interference in daily life at baseline according to the patient; however, according to the investigator, they were mood and quality/quantity of sleep, although none of them were significant. But changes in the score of the interference questionnaire between visits were not statistically significantly related to the control of the disease. However, average score according to both investigator and patients showed a significant correlation with ECOG status.
Conclusion
The first-line treatment of NSCLC is correlated with an improvement in the symptomatic evolution of advanced NSCLC patients.
Funding
Roche.
Similar content being viewed by others
References
Sociedad Española de Oncología Médica (SEOM). Las Cifras del Cáncer en España 2019. SEOM. https://seom.org/dmcancer/wp-content/uploads/2019/informe-SEOM-cifras-cancer-2019.pdf.
Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–57.
Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib vs. chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368:2385–94.
Solomon BJ, Mok T, Kim DW, et al. First line crizotinib vs. chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371:2167–77.
Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371:1963–71.
Wu YL, Fukuoka M, Mok TS, et al. Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study. Lung Cancer. 2013;81(2):280–7.
Brabo EP, Paschoal ME, Biasoli I, Nogueira FE, Gomes MC, Gomes IP. Brazilian version of the QLQ-LC13 lung cancer module of the European Organization for Research and Treatment of Cancer: preliminary reliability and validity report. Qual Life Res. 2006;15(9):1519–24.
Sandler A, Grey R, Perry MC, et al. Paclitaxel–Carboplatin alone or with bevacizumab for non–small-cell lung cancer. N Engl J Med. 2006;355:2542–50.
Reck M, von Pawell J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009;27:1227–34.
Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543–51.
Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non–small-cell lung cancer. N Engl J Med. 2002;346:92–8.
Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-Positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823–33.
Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung Cancer. N Engl J Med. 2018;378:2078–92.
Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379:2040–51.
Wang XS, Shi Q, Lu C, Basch EM, Johnson VE, Mendoza TR, et al. Prognostic value of symptom burden for overall survival in patients receiving chemotherapy for advanced nonsmall cell lung cancer. Cancer. 2010;116:137–45.
Wang XS, Fairclough DL, Liao Z, Komaki R, Chang JY, Mobley GM, Cleeland CS. Longitudinal study of the relationship between chemoradiation therapy for non–small-cell lung cancer and patient symptoms. J Clin Oncol. 2006;24:4485–91.
Hollen PJ, Gralla RJ, Kris MG, Potanovich LM. Quality of life assessment in individuals with lung cancer: Testing the lung cancer symptom scale (LCSS). Eur J Cancer. 1993;29A:S51–8.
Ettinger DS. Lung cancer and other pulmonary neoplasms. In: Goldman L, Schafer AI, editors. Goldman’s Cecil medicine, vol. 2. 24th ed. New York: Elsevier; 2012. p. 1264–71.
Bezjak A, Tu D, Seymour L, Clark G, Trajkovic A, Zukin M, et al. Symptom improvement in lung cancer patients treated with erlotinib: Quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol. 2006;24:3831–7.
Butler L, Bacon M, Carey M, et al. Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy clinical trial. J Clin Oncol. 2004;22:2461–68.
Iyer S, Roughley A, Rider A, Taylor-Stokes G. The symptom burden of non-small cell lung cancer in the USA: A real-world cross-sectional study. Support Care Cancer. 2014;22:181–7.
Temel JS, Pirl WF, Lynch TJ. Comprehensive symptom management in patients with advanced-stage non-small-cell lung cancer. Clin Lung Cancer. 2006;7:241–9.
Rolski J, Zemełka T, Jasiówka M, Czyzewicz G, Kojs-Pasińska E. Chemotherapy of advanced non small cell lung cancer: Effect on survival and symptoms affecting quality of life. Pneumonol Alergol Pol. 2007;75:343–8.
Davidoff AJ, Tang M, Seal B, Edelman MJ. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin oncol. 2010;28:2191–97.
Burdett S, David J, Stewart L, Tierney J, Le Pechoux C. On behalf of the NSCLC Collaborative Group. Supportive Care and chemotherapy vs. supportive care alone in advanced non-small cell lung cancer (NSCLC): a meta-analysis using individual patient data from randomized controlled trials. J Thor Oncol 2007;2:S337.
Milanowski J, Szmygin-Milanowska K. Treatment of non-small cell lung cancer: Where we are? Pneumonol Alergol Pol. 2013;81(1):55–60.
Acknowledgements
The authors would like to thank all the researchers for their participation in the study.
Funding
Sponsorship for this study and article processing charges were funded by Roche. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis.
Medical Writing and Other Assistance
The realization of this study has been possible thanks to the funding of Roche and the logistical and technical support (including medical writing) of IQVIA.
Authorship
All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.
Disclosures
Manuel Dómine, Bartomeu Massuti, Javier Puente, Antonio Calles, Emilio Esteban, Eduardo Triguboff, Yashmin Silvana Afonzo, Regina Gironés, Francisco Aparisi and Juana Oramas have nothing to disclose.
Compliance with Ethics Guidelines
The study was approved by the Spanish Agency of Medicines and Medical Devices and by the Ethics Committee of the Hospital Universitario de Canarias. The data was collected between May 2011 and April 2012. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee of Hospital Universitario de Canarias (Spain) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.
Data Availability
The data contained in our database contains proprietary elements owned by Roche and, therefore, cannot be broadly disclosed or made publicly available. The datasets generated and/or analyzed during the current study are available on reasonable request.
Author information
Authors and Affiliations
Corresponding author
Additional information
Enhanced Digital Features
To view enhanced digital features for this article go to https://doi.org/10.6084/m9.figshare.7831247.
Rights and permissions
About this article
Cite this article
Dómine, M., Massuti, B., Puente, J. et al. Observational Prospective Study to Determine the Evolution of the Symptomatic Profile of Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients and Its Relation to the Control of the Disease. Adv Ther 36, 1497–1508 (2019). https://doi.org/10.1007/s12325-019-00931-8
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-019-00931-8